Published in J Virol on July 30, 2008
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57
Specificity of the autologous neutralizing antibody response. Curr Opin HIV AIDS (2009) 1.30
Envelope vaccination shapes viral envelope evolution following simian immunodeficiency virus infection in rhesus monkeys. J Virol (2009) 1.04
Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys. J Virol (2010) 1.01
Tsetse salivary gland hypertrophy virus: hope or hindrance for tsetse control? PLoS Negl Trop Dis (2011) 0.99
Sequential evolution and escape from neutralization of simian immunodeficiency virus SIVsmE660 clones in rhesus macaques. J Virol (2012) 0.95
Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies. J Virol (2012) 0.90
Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies. J Virol (2008) 0.89
Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein. J Virol (2011) 0.87
Functional contributions of carbohydrate on AIDS virus glycoprotein. Yale J Biol Med (2010) 0.87
Balancing reversion of cytotoxic T-lymphocyte and neutralizing antibody escape mutations within human immunodeficiency virus type 1 Env upon transmission. J Virol (2009) 0.83
Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy. PLoS Pathog (2010) 0.80
Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys. J Virol (2012) 0.79
Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein. J Immunol (2014) 0.78
PAML: a program package for phylogenetic analysis by maximum likelihood. Comput Appl Biosci (1997) 45.07
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 24.69
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science (1995) 18.40
Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75
The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science (1998) 12.52
The antigenic structure of the HIV gp120 envelope glycoprotein. Nature (1998) 12.44
Likelihood models for detecting positively selected amino acid sites and applications to the HIV-1 envelope gene. Genetics (1998) 11.25
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol (1993) 10.75
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science (1998) 8.36
Structure of an unliganded simian immunodeficiency virus gp120 core. Nature (2005) 8.30
Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science (1990) 8.07
Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol (1990) 7.85
Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature (2006) 6.78
The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. AIDS Res Hum Retroviruses (1990) 5.79
Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol (2005) 5.76
HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol (2004) 5.18
Insufficient production and tissue delivery of CD4+ memory T cells in rapidly progressive simian immunodeficiency virus infection. J Exp Med (2004) 3.62
Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys. J Virol (1991) 3.46
Accuracy and power of bayes prediction of amino acid sites under positive selection. Mol Biol Evol (2002) 3.26
Complex determinants of macrophage tropism in env of simian immunodeficiency virus. J Virol (1992) 3.16
HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS (1995) 3.08
Genetic diversity and evolution of retroviruses. Curr Top Microbiol Immunol (1992) 2.92
Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell (1988) 2.91
Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. J Virol (1997) 2.90
Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS. J Virol (1991) 2.84
Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog (2006) 2.81
Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys. J Virol (1993) 2.65
Titration and characterization of two rhesus-derived SIVmac challenge stocks. AIDS Res Hum Retroviruses (1994) 2.63
Viral persistence: HIV's strategies of immune system evasion. Annu Rev Med (2002) 2.51
Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. Proc Natl Acad Sci U S A (1998) 2.46
Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J Virol (2006) 2.33
A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J Virol (2002) 1.97
In vitro generation of an HTLV-III variant by neutralizing antibody. J Immunol (1986) 1.91
Analysis of simian immunodeficiency virus sequence variation in tissues of rhesus macaques with simian AIDS. J Virol (1993) 1.77
The crystal structure of the SIV gp41 ectodomain at 1.47 A resolution. J Struct Biol (1999) 1.76
The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope. J Virol (1990) 1.76
Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain. Virology (2001) 1.52
Widespread adaptive evolution in the human immunodeficiency virus type 1 genome. J Mol Evol (2003) 1.49
Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change. J Virol (1994) 1.40
Antigenic variation of SIV: mutations in V4 alter the neutralization profile. Virology (1996) 1.35
The power of phylogenetic comparison in revealing protein function. Proc Natl Acad Sci U S A (2005) 1.31
Strategies used by human immunodeficiency virus that allow persistent viral replication. Nat Med (1999) 1.31
Effects of natural sequence variation on recognition by monoclonal antibodies neutralize simian immunodeficiency virus infectivity. J Virol (1994) 1.25
Importance of B-cell responses for immunological control of variant strains of simian immunodeficiency virus. J Virol (2003) 1.24
Suboptimal nucleotides in the infectious, pathogenic simian immunodeficiency virus clone SIVmac239. J Virol (2001) 1.17
Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus. J Virol (2005) 1.13
Isolation and characterization of a neuropathogenic simian immunodeficiency virus derived from a sooty mangabey. J Virol (1998) 1.11
Immune evasion strategies of the primate lentiviruses. Immunol Rev (2001) 0.97
Effects of mutations in constant regions 3 and 4 of envelope of simian immunodeficiency virus. Virology (1995) 0.97
Adaptation of a diverse simian immunodeficiency virus population to a new host is revealed through a systematic approach to identify amino acid sites under selection. Mol Biol Evol (2006) 0.80
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 9.30
Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med (2009) 7.33
Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature (2006) 6.78
Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med (2004) 6.33
Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol (2005) 5.76
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Glycerol monolaurate prevents mucosal SIV transmission. Nature (2009) 5.02
Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest (2005) 5.00
Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog (2006) 4.80
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol (2006) 4.26
Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog (2009) 4.24
Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med (2009) 4.22
Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog (2009) 4.18
Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med (2007) 4.14
Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science (2004) 3.95
A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Biol Chem (2003) 3.70
Insufficient production and tissue delivery of CD4+ memory T cells in rapidly progressive simian immunodeficiency virus infection. J Exp Med (2004) 3.62
Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol (2007) 3.61
Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol (2007) 3.59
Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J Virol (2006) 3.59
Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med (2007) 3.45
Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood (2003) 3.40
Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science (2013) 3.27
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med (2009) 3.25
TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol (2010) 3.21
SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans. AIDS (2002) 3.19
Immune clearance of highly pathogenic SIV infection. Nature (2013) 3.15
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature (2013) 3.14
Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol (2004) 3.12
Premature induction of an immunosuppressive regulatory T cell response during acute simian immunodeficiency virus infection. J Infect Dis (2006) 3.04
Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci U S A (2003) 3.02
HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol (2006) 2.72
Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. Proc Natl Acad Sci U S A (2004) 2.57
Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog (2010) 2.55
Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest (2011) 2.55
Viral persistence: HIV's strategies of immune system evasion. Annu Rev Med (2002) 2.51
IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates. J Clin Invest (2006) 2.41
Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol (2009) 2.38
Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med (2003) 2.37
Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J Virol (2006) 2.33
New paradigms for HIV/AIDS vaccine development. Annu Rev Med (2011) 2.21
CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood (2005) 2.21
Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5alpha. Proc Natl Acad Sci U S A (2006) 2.16
Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. PLoS Pathog (2007) 2.14
Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J Virol (2005) 2.01
A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J Virol (2002) 1.97
The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection. J Infect Dis (2002) 1.90
Simian immunodeficiency virus-induced lymphatic tissue fibrosis is mediated by transforming growth factor beta 1-positive regulatory T cells and begins in early infection. J Infect Dis (2007) 1.87
Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med (2012) 1.86
Generation of simian-tropic HIV-1 by restriction factor evasion. Science (2006) 1.84
High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol (2009) 1.82
Reduced inflammation and lymphoid tissue immunopathology in rhesus macaques receiving anti-tumor necrosis factor treatment during primary simian immunodeficiency virus infection. J Infect Dis (2012) 1.80
Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV neuroAIDS. J Clin Invest (2005) 1.78
Vaccine-induced CD8+ T cells control AIDS virus replication. Nature (2012) 1.78
Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis (2011) 1.76
A macaque model of HIV-1 infection. Proc Natl Acad Sci U S A (2009) 1.76
Analysis of copy number variation in the rhesus macaque genome identifies candidate loci for evolutionary and human disease studies. Hum Mol Genet (2008) 1.73
Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol (2002) 1.67
CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J Virol (2002) 1.66
A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med (2013) 1.62
Differential infection patterns of CD4+ T cells and lymphoid tissue viral burden distinguish progressive and nonprogressive lentiviral infections. Blood (2012) 1.62
Numb links extracellular cues to intracellular polarity machinery to promote chemotaxis. Dev Cell (2011) 1.60
TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. Blood (2004) 1.60
ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog (2012) 1.60
Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system. J Virol (2003) 1.60
Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS One (2008) 1.57
Induction of a virus-specific effector-memory CD4+ T cell response by attenuated SIV infection. J Exp Med (2006) 1.55
Simian immunodeficiency virus infection in neonatal macaques. J Virol (2003) 1.54
Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J Virol (2003) 1.53
3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells. Proc Natl Acad Sci U S A (2010) 1.52
Profound CD4+/CCR5+ T cell expansion is induced by CD8+ lymphocyte depletion but does not account for accelerated SIV pathogenesis. J Exp Med (2009) 1.51
Pol-specific CD8+ T cells recognize simian immunodeficiency virus-infected cells prior to Nef-mediated major histocompatibility complex class I downregulation. J Virol (2007) 1.47
Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. J Virol (2002) 1.44
Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity. J Virol (2004) 1.44
Cell tropism of simian immunodeficiency virus in culture is not predictive of in vivo tropism or pathogenesis. Am J Pathol (2004) 1.43
Cloning and analysis of microRNAs encoded by the primate gamma-herpesvirus rhesus monkey rhadinovirus. Virology (2007) 1.40
MHC heterozygote advantage in simian immunodeficiency virus-infected Mauritian cynomolgus macaques. Sci Transl Med (2010) 1.38
Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished alpha interferon production in vitro. J Virol (2008) 1.36